![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, February 25, 2022 7:14:32 PM
I overstated by saying "shut off" the Big Pharma Covid revenue stream. But if a vaccinated patient gets lenz after becoming reinfected following his 1st dose of a vaccine, lenz could eliminate a 2nd, 3rd, or 4th vaccination. So a significant portion of the Big Pharma revenue could be eliminated. That's enough incentive to pose a competitive challenge to the vaccine market.
I'd like to see lenz compounded in order to infuse enough of an infection to activate lenz, and then take ALL of the Covid vaccine market (which, in reality, would create an actual vaccine market, which we don't really have yet). But I already said that I have no idea if that is feasible. I just think that it may be. And I definitely think lenz could be administered in an outpatient setting, to those with a Covid diagnosis and elevated CRP levels.
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM